Therapy Trends: Alzheimer's Disease - Breaking new ground in disease modification

Introduction

Introduction

In 2012, the Alzheimer’s disease (AD) market was dealt a huge blow following negative results from pivotal Phase III trials of Pfizer and J&J’s bapineuzumab and the intravenous formulation of the drug was discontinued. Expectations for beta-amyloid theory were low following this failure; however results from Eli Lilly’s solanezumab have offered a glimmer of hope for the AD community. Although missing its primary endpoints, pooled analysis of solanezumab data in mild patients showed a statistical significant slowdown of cognitive decline.

With novel therapies slowly emerging from the pipeline, such as beta secretase and tau therapies, and positive research into biomarkers to aid early AD diagnosis there is renewed hope as the market enters a new phase of development.

The KOL Insight module of Alzheimer’s Disease: Beta-amyloid light fases to leave development hole is compiled from exclusive, in-depth interviews with the world’s leading KOLs in AD. It identifies and analyses the major factors, advances and trends currently influencing the AD treatment landscape. The report focuses on late-stage pipeline products, and how these could modify future AD management.

FirstWord selected the KOLs for this Therapy Trends report based on their level of engagement and influence within the AD pharmaceutical industry, and their scientific standing. Our unique KOL scoring system identifies those thought-leaders with the greatest insight into how AD clinical research will shape the future market.

Scope

Key Benefits

Alzheimer’s disease: Beta-amyloid light fades to leave development hole examines the most prominent insights gained from the field’s key opinion leaders. The results of FirstWord’s research and analysis will help you to:

Highlights

Alzheimer’s disease: Beta-amyloid light fades to leave development hole answers key questions including:

•What do KOLs make of the sola and bapi failures?

Puchase Reasons

Alzheimer’s Disease Panel of Key Opinion Leaders

FirstWord selected the KOLs for this Therapy Trends report based on their level of engagement and influence within the AD pharmaceutical industry, and their scientific standing. The AD panel assembled for this Therapy Trends research is drawn from North America and Europe professionals:

Event Assessments

Stay a step ahead with Therapy Trends Event Assessments. Over the next 12 months, you will receive updated qualitative analysis each time a major market event breaks. Updates will be delivered straight into your inbox within days of each event’s occurrence.

Whether it’s a predicted product approval or an unexpected late stage failure, Therapy Trends has the resources and knowledge to keep you up to date with the latest market analysis.

Methodology

This report provides a qualitative overview of the current and future Alzheimer’s disease (AD) market. Information was gathered from telephone discussions held with twelve key opinion leaders (KOLs), from across the major AD markets, including France, Germany, Italy, the UK and the US. These regions were selected because they contain many of the largest global markets for the pharmaceutical industry, and also dictate the dynamics of Pharma markets in other countries.

In order to critically select Key Opinion Leaders (KOLs) a number of parameters were considered including their clinical experience, scientific publications, involvement with Pharma, involvement in clinical trials, and record of presenting at high profile international conferences.

Subject matter for discussion in the interviews covered future diagnostic and therapeutic strategies for AD, the future of AD drug classes, and new drugs entering the market. These leading KOLs also gave their views on current research, the usefulness of existing AD drug classes, the cost of newer drugs and other concerns in the therapy area.

Table of Contents
for Therapy Trends: Alzheimer's Disease - Breaking new ground in disease modification

• 1.Current Alzheimer’s disease marketplace

  2.Current treatment landscape

  3.Reimbursement of key Alzheimer’s disease brands

  4.Current therapies

  5.Aricept (donepezil; Eiasi/Pfizer) trends

  6.Exelon (rivastigmine; Novartis) trends

  7.Razadyne (galantamine; Johnson & Johnson/Shire) trends

  8.Namenda/Ebixa (memantine; Forest/Merz/Lundbeck) trends

  9.Current treatment algorithm

  10.Unmet needs in Alzheimer’s disease

  11.Pipeline Alzheimer’s disease therapies

  12.Beta-amyloid overview

  13.Solanezumab (LY2062430, Eli Lilly) trends

  14.Gammagard (immune globulin IV [human], Baxter) trends

  15.Gantenerumab (Roche) trends

  16.Bapineuzumab (Johnson & Johnson/Pfizer) trends

  17.BACE inhibitor overview

  18.MK-8931 (Merck) trends

  19.Future prescribing trends

  20.Future developments in Alzheimer’s disease

  21.Clear definition of disease-modifying is required

  22.Improved understanding of underlying disease etiology

  23.Therapies targeting tau

  24.Gene therapy as a treatment option

  25.Enrolment of trials will be more important for success

  26.Identification of patients earlier in disease course for intervention

  27.Development of biomarkers will aid diagnosis and treatment

Additional Details

Publisher

FirstWord Pharma

Publisher Information

Reference

16 |

Number of Pages

162

Report Format

PDF

Related Reports